<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01349842</url>
  </required_header>
  <id_info>
    <org_study_id>IC 2009-03</org_study_id>
    <nct_id>NCT01349842</nct_id>
  </id_info>
  <brief_title>Circulating Tumor Cells to Guide Chemotherapy for Metastatic Breast Cancer</brief_title>
  <acronym>CirCé01</acronym>
  <official_title>CirCe01 Study: Evaluation of the Use of Circulating Tumour Cells to Guide Chemotherapy From the 3rd Line of Chemotherapy for Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Curie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the use of Circulating tumour Cells to guide chemotherapy from the 3rd line of
      chemotherapy for metastatic breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase III multicentre, randomized, open-label study comparing early evaluation of the
      efficacy of chemotherapy by determination of circulating tumour cells versus conventional
      clinical and radiological evaluation.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>7 years</time_frame>
    <description>Overall survival (from date of randomization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure of safety and tolerability</measure>
    <time_frame>7 years</time_frame>
    <description>A list of the most frequent toxicity was established. The ranks 3 and 4 will be more specificaly collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of quality of life</measure>
    <time_frame>7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression, to discontinuation of therapy after 3rd line.</measure>
    <time_frame>7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of CTC with usual serum tumour markers</measure>
    <time_frame>7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medico-economical analysis</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate the clinical interest, in particular forecast, of the circulating tumoral DNA</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">265</enrollment>
  <condition>Breast Cancer Ductal Infiltrating Metastatic</condition>
  <arm_group>
    <arm_group_label>Circulating Tumor Cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Centralized determination of CTC by CellSearch® technology (Veridex), the only technology currently validated in clinical practice for the early evaluation of response to chemotherapy of breast cancers. This evaluation is performed by blood sampling comparing the CTC level before the first injection of each new line of chemotherapy. Chemotherapy can only be continued in the case of a positive CTC response. Discontinuation of chemotherapy can also be decided by the clinician on the basis of other clinical or radiological arguments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clinical and radiological criteria</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Management of chemotherapy according to the usual clinical and radiological criteria adopted by the patient's attending physician.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>20ml of patient peripherical blood will be collected</description>
    <arm_group_label>Circulating Tumor Cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual clinical and radiological criteria</intervention_name>
    <description>Clinical examination, tumoral evaluation</description>
    <arm_group_label>Clinical and radiological criteria</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women over the age of 18 years.

          -  WHO performance status: 0 to 4.

          -  Metastatic breast cancer.

          -  Progression after 2 lines of chemotherapy with decision to initiate third-line
             chemotherapy.

          -  Disease evaluable by CTC (CTC-positive before starting chemotherapy).

          -  Histology: lobular or ductal adenocarcinoma.

          -  Information of the patient and signature of the informed consent form by the patient
             or her legal representative.

        Exclusion Criteria:

          -  Disease not evaluable by CTC (CTC-negative before starting chemotherapy).

          -  History of other potentially metastatic cancer (stage III or IV cancer) different from
             breast cancer.

          -  Histology other than lobular or ductal adenocarcinoma.

          -  Pregnant woman, women likely to become pregnant or nursing mothers.

          -  Persons deprived of their freedom or under guardianship.

          -  Women unable to comply with the medical follow-up of the study for geographical,
             social or mental reasons.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>PIERGA Jean-Yves, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Curie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Georges Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Victor Hugo</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Rene Huguenin Curie</name>
      <address>
        <city>Saint Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Canacerologie de L'Ouest</name>
      <address>
        <city>Saint-herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2011</study_first_submitted>
  <study_first_submitted_qc>May 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2011</study_first_posted>
  <last_update_submitted>August 1, 2016</last_update_submitted>
  <last_update_submitted_qc>August 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplastic Cells, Circulating</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

